Trial Profile

A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Sep 2024 According to an Incyte Corporation media release, data from this study will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2024 held September 25-28 in Amsterdam.
19 Mar 2024 Status changed from active, no longer recruiting to completed.
11 Mar 2024 According to an Incyte Corporation media release, the company announced new results as a late-breaking oral presentation (Session S050 Late-Breaking Research Session 2) at the American Academy of Dermatology (AAD) Annual Meeting, held from March 8 to 2, 2024, in San Diego.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com